Literature DB >> 16130136

Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study.

George R Prout1, Margaret N Wesley, Rosemary Yancik, Lynn A G Ries, Richard J Havlik, Brenda K Edwards.   

Abstract

BACKGROUND: Bladder carcinoma often occurs in older patients who also may have other comorbid conditions that could influence the administration of surgical therapy. The current study was conducted to describe the distribution of comorbid conditions in patients with bladder carcinoma and ascertain whether these conditions, as grouped by the American Society of Anesthesiologists physical status classification, affected the choice of surgical therapy.
METHODS: The authors examined six population-based cancer registries from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program in 1992. A total of 820 individuals age 55 years and older was found. A random sample of newly diagnosed bladder carcinoma patients were stratified according to registry, age group (ages 55-64 yrs, ages 65-74 yrs, and age 75 yrs and older), and gender. Data regarding comorbid conditions were abstracted from the medical records and merged with routinely collected cancer registry data. The main outcome measures were the prevalence and distribution of comorbid conditions, American Society of Anesthesiologists physical status classification, and the receipt of cystectomy in patients with muscle invasion.
RESULTS: Hypertension, chronic pulmonary disease, arthritis, and heart disease were found to affect at least 15% of the study population. Approximately 38% of patients were current or former smokers. Greater than 90% of patients with superficial disease were treated with transurethral resection alone. Among those patients with muscle invasion, only 55% of those ages 55-59 years underwent cystectomy; this percentage dropped to 4% in patients age 85 years and older. Among patients with an American Society of Anesthesiologists physical status classification of 0-2, the cystectomy rate ranged from 53% in those ages 55-59 years to 9% in those age 85 years and older.
CONCLUSIONS: There were no significant treatment differences noted with regard to age among patients with superficial disease. Among those patients with muscle invasion, those age 75 years and older were less likely to undergo radical cystectomy (14%) compared with patients ages 55-64 years (48%) and those ages 65-74 years (43%). Patient age may contribute to treatment decisions in patients with muscle-invasive disease, even when comorbidity is taken into account. Copyright 2005 American Cancer Society

Entities:  

Mesh:

Year:  2005        PMID: 16130136     DOI: 10.1002/cncr.21354

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

Review 1.  [Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies].

Authors:  M Rink; F K Chun; T F Chromecki; H Fajkovic; R Dahlem; M Fisch; S F Shariat
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

2.  Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.

Authors:  Thomas F Chromecki; Julian Mauermann; Eugene K Cha; Robert S Svatek; Harun Fajkovic; Pierre I Karakiewicz; Yair Lotan; Derya Tilki; Patrick J Bastian; Bjoern G Volkmer; Francesco Montorsi; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Vincenzo Ficarra; Christian G Stief; Colin P Dinney; Eila Skinner; Karl Pummer; Yves Fradet; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

3.  Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy.

Authors:  Thomas F Chromecki; Behfar Ehdaie; Giacomo Novara; Karl Pummer; Richard Zigeuner; Christian Seitz; Armin Pycha; Richard K Lee; Eugene K Cha; Pierre I Karakiewicz; Casey Ng; Jay D Raman; Felix K Chun; Hans-Martin Fritsche; Kazumasa Matsumoto; Wassim Kassouf; Thomas J Walton; Patrick J Bastian; Juan I Martínez-Salamanca; Douglas S Scherr; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-04-17       Impact factor: 4.226

Review 4.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 5.  Bladder cancer in the elderly.

Authors:  Shahrokh F Shariat; Matthew Milowsky; Michael J Droller
Journal:  Urol Oncol       Date:  2009 Nov-Dec       Impact factor: 3.498

6.  Significance of age and comorbidity as prognostic indicators for patients with bladder cancer.

Authors:  Moon Soo Ha; In Ho Chang
Journal:  Asian J Androl       Date:  2010-08-02       Impact factor: 3.285

7.  Geriatric oncology: an overview of progresses and challenges.

Authors:  Martine Extermann
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

8.  Treatment and outcome in muscle invasive bladder cancer: a population-based survey.

Authors:  Anna M Leliveld; Benjamin H J Doornweerd; Esther Bastiaannet; Michael Schaapveld; Igle J de Jong
Journal:  World J Urol       Date:  2010-04-10       Impact factor: 4.226

9.  Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

Authors:  Husain K Khambati; Toni K Choueiri; Christian K Kollmannsberger; Scott North; George A Bjarnason; Ulka N Vaishampayan; Lori Wood; Jennifer J Knox; Min-Han Tan; Mary J MacKenzie; Frede Donskov; Brian I Rini; Daniel Y C Heng
Journal:  Clin Genitourin Cancer       Date:  2014-03-05       Impact factor: 2.872

Review 10.  Bladder cancer.

Authors:  David J Gallagher; Matthew I Milowsky
Journal:  Curr Treat Options Oncol       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.